Quince Therapeutics Appoints Dr. Charles S. Ryan as President

Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, today announced the appointment of Charles S. Ryan, J.D., Ph.D. as President. In this new position, Dr. Ryan will be responsible for the company’s corporate legal activities and intellectual property portfolio, and pending the completion of its planned acquisition of EryDel S.p.A., the international integration of financial and operational activities and ongoing business operations of Quince.

Dirk Thye, M.D., Quince’s Chief Executive Officer, said, “Charles is a valuable addition to our management team. His considerable expertise will help enhance efficiency and effectiveness across our research programs and business operations. I have known Charles and his work for many years, during which he has repeatedly demonstrated a broad and impressive skill set in many areas of business, research, and law. His contributions to the ongoing management of our legal, IP, and upon completion, the integration of the Italian business and ongoing operations, will be critical in both the near and longer term.”

Dr. Ryan, Quince’s President, said, “Quince and the EryDel assets would represent an exciting opportunity to advance a first-to-market treatment for pediatric patients suffering from the fatal rare neurological disease, Ataxia-Telangiectasia (A-T). Pending completion of the transaction, I look forward to working closely with Quince’s management and talented EryDel team to advance a potentially breakthrough therapy to these long-underserved patients.”

Dr. Ryan brings an extensive background in pharmaceuticals and biotechnology. Most notably, he served as Senior Vice President and Chief Intellectual Property Counsel at Forest Laboratories (now AbbVie) for more than 10 years where he managed several intellectual property estates spanning CNS, cardiovascular, gastrointestinal, respiratory, and anti-infective therapeutic areas. He also worked closely with the commercial and development teams, as well as the business development teams at Forest.

Most recently, Dr. Ryan served as President, Chief Executive Officer, and Chairman of Travecta Therapeutics, a private biopharmaceutical company pioneering transformative treatments for serious neurological conditions. Prior to that, he served as Chief Executive Officer and Director of Neurotrope, Inc., a clinical-stage biopharmaceutical company developing targeted, novel regenerative therapeutics for neurodegenerative diseases and developmental disorders. Dr. Ryan holds a J.D. from Western New England University, a Ph.D. in Oral Biology and Pathology from Stony Brook University, and a B.A. in Chemistry from The College of Wooster. He is a member of the New York State Bar and is a patent practitioner of the U.S. Patent and Trademark Office.

About Quince Therapeutics

Quince Therapeutics is a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform the lives of patients suffering from debilitating and rare diseases. For more information, visit www.quincetx.com and follow Quince Therapeutics on LinkedIn and @Quince_Tx on Twitter.

Forward-looking Statements

Statements in this news release contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements contained in this news release may be identified by the use of words such as “believe,” “may,” “should,” “expect,” “anticipate,” “plan,” “believe,” “estimated,” “potential,” “intend,” “will,” “can,” “seek,” or other similar words. Examples of forward-looking statements include, among others, statements relating to Quince’s planned acquisition of EryDel and expected benefits of the transaction. Forward-looking statements are based on Quince’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in the company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 3, 2023, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince undertakes no duty to update such information except as required under applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230906220898/en/